The impact of kidney function on the outcome of metastatic renal cell carcinoma patients treated with vascular endothelial growth factor-targeted therapy

Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency

(2010) G. Khan et al.   ANNALS OF ONCOLOGY

Cancer Statistics, 2009

(2009) A. Jemal et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Tolerance of Sunitinib in Dialyzed Patients With Metastatic Renal Cell Carcinoma

(2009) Michael M. Vickers et al.   Clinical Genitourinary Cancer

Phase I and Pharmacokinetic Study of Sorafenib in Patients With Hepatic or Renal Dysfunction: CALGB 60301

(2009) Antonius A. Miller et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor–Targeted Agents: Results From a Large, Multicenter Study

(2009) Daniel Y.C. Heng et al.   JOURNAL OF CLINICAL ONCOLOGY

Pharmacokinetics and Safety of Sunitinib Malate in Subjects With Impaired Renal Function

(2009) Reza Khosravan et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Treatment of Metastatic Renal Cell Cancer with Sunitinib During Chronic Hemodialysis

(2009) Stefan Zastrow et al.   UROLOGY

A Population-based Analysis of the Rate of Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma in the United States

(2009) Claudio Jeldres et al.   UROLOGY

Pharmacokinetics of sunitinib in hemodialysis

(2008) H. Izzedine et al.   ANNALS OF ONCOLOGY

Nephrectomy improves the survival of patients with locally advanced renal cell carcinoma

(2008) Laurent Zini et al.   BJU INTERNATIONAL

Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma

(2008) Robert J. Motzer et al.   CANCER

Population-based Assessment of Survival After Cytoreductive Nephrectomy Versus No Surgery in Patients With Metastatic Renal Cell Carcinoma

(2008) Laurent Zini et al.   UROLOGY